Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi AppTec Bioanalytical Service Unit Passes FDA Inspection | Contract Pharma
Breaking News

WuXi AppTec Bioanalytical Service Unit Passes FDA Inspection

Shanghai facility successfully completes audit and bioequivalence inspection

WuXi AppTec’s Lab Testing Division’s Bioanalytical facility in Shanghai has passed U.S. FDA’s bioequivalence (BE) inspection with no 483 observations.

The FDA inspectors audited WuXi’s quality system during the 5-day inspection, focusing on scientific data integrity, operation infrastructure, equipment, sample storage, archival system, quality control, and quality assurance. The inspection covered two bioequivalence studies for pre-approval including method validation and sample analysis and eight other clinical bioanalytical studies from 2013 and 2016 as a general regulatory compliance inspection.

“FDA has the most stringent requirement on quality and data integrity among international regulatory agencies. We are proud with the result of this audit,” says Dr. Jason Liu, Senior Vice President and Chief Operating Officer of Lab Testing Division. “We will continue to maintain the highest quality standards, and provide the best-in-class R&D services for our customers worldwide.”
 
WuXi AppTec provides small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and molecular testing and genomics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters